Regular paper
The binding interactions of Ro 40-5967 at the L-type Ca2+ channel in cardiac tissue

https://doi.org/10.1016/0014-2999(95)00194-PGet rights and content

Abstract

Ro 40-5967 [(1S,2S)-2-[2[3-(2-benzamidopropyl]-methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthyl-methoxyacetate] is a new Ca2+ channel antagonist active at L-type channels. Radioligand binding studies in cardiac tissue show that Ro 40-5967 does not inhibit 1,4-dihydropyridine binding, but does inhibit diltiazem, desmethoxyverapamil and SR 33557 binding with IC50 values of 8 × 10−9, 10−8 and 5 × 10−8 M, respectively. Equilibrium and kinetic binding studies showed that Ro 40-5967 inhibited both desmethoxyverapamil and SR 33557 binding in an apparently competitive manner. Ro 40-5967 defines an additional and possibly unique antagonist binding site on the L-type voltage-gated Ca2+ channel.

References (24)

  • J.-P. Clozel et al.

    Ro 40-5967: a new nondihydropyridine calcium antagonist

    Cardiovasc. Drug Rev.

    (1991)
  • R.J. Gould et al.

    Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists

  • Cited by (66)

    • Desmethoxyverapamil

      2007, xPharm: The Comprehensive Pharmacology Reference
    • Marrubenol interacts with the phenylalkylamine binding site of the L-type calcium channel

      2004, European Journal of Pharmacology
      Citation Excerpt :

      The material banding at the interface was collected and designated plasma-membrane fraction. (−)-[3H]Desmethoxyverapamil ([3H]D888) binding was measured as described by Rutledge and Triggle (1995), with small modifications. Membranes (25–50 μg protein) were incubated with [3H]D888 for 90 min at 25 °C, in the presence of 50 mM Tris/HCl (pH 7.4) and bovine serum albumin ( 0.01%).

    View all citing articles on Scopus
    View full text